Coordinated Interferon-γ/Tumor Necrosis Factor Axis Drives Selective Loss of Activated Enteric Glia in Inflammatory Bowel Diseases

Read full text
Authors: Marvin Bubeck, Klara Penkert, Heidi Limberger, Miguel Gonzalez Acera, Christina Plattner, Svenja Ziegler, Anoohya N. Muppirala, Patrycja M. Forster, Manuel O. Jakob, Reyes Gámez‐Belmonte, Lena Erkert, Subhash Kulkarni
+56 more Claudia Günther, Raja Narayana Atreya, Anja A. Kuehl, Ahmed Nabil Hegazy, Kai Hildner, Zlatko Trajanoski, Britta Siegmund, Markus F. Neurath, Imke Atreya, Raja Atreya, Petra Bacher, Christoph Becker, Christian Bojarski, Nathalie Britzen-Laurent, Caroline Voskens, Hyun-Dong Chang, Andreas Diefenbach, Claudia Günther, Ahmed Nabil Hegazy, Kai Hildner, Christoph S. N. Klose, Kristina Koop, Susanne M. Krug, Anja A. Kühl, Moritz Leppkes, Rocío López-Posadas, Leif S. Ludwig, Clemens Neufert, Markus F. Neurath, Jay V. Patankar, Christina Plattner, Magdalena S. Prüß, Andreas Radbruch, Chiara Romagnani, Francesca Ronchi, Ashley D. Sanders, Alexander Scheffold, Jörg-Dieter Schulzke, Michael Schumann, Sebastian Schürmann, Britta Siegmund, Michael Stürzl, Zlatko Trajanoski, Antigoni Triantafyllopoulou, Maximilian Waldner, Carl Weidinger, Stefan Wirtz, Sebastian Zundler, Meenakshi Rao, Fränze Progatzky, Dieter Chichung Lie, Christoph Becker, Chiara Romagnani, Leif S. Ludwig, Christoph S. N. Klose, Jay V. Patankar
Cited by: 0
References: 59

Abstract

Abstract Background Enteric glial cells (EGC) play a crucial role in maintaining gut homeostasis, but their dysregulation in inflammatory bowel diseases (IBD) remains poorly understood. Emerging preclinical data suggests activated EGC have beneficial roles in controlling gut pathophysiology. Objective Understanding EGC activation and adaptation during experimental and clinical IBD. Design We provide the first highly integrated approach to identify EGC activation signature in IBD. Profiling 390 samples from IBD patients via bulk and single-nucleus (sn) transcriptomics and replicate the findings on publicly available bulk and single-cell (sc) datasets from 1160 patients and 19,000 single EGC. Preclinical modelling of Th1/Th17 inflammation, reporter-assisted EGC sorting, analysis of regulated cell death, and Casp8 ablation in EGC was performed Results We identified novel IBD type and sampling associated EGC activation signature. Specific EGC activation markers were shared in biopsies and resection specimens, and were divergent between Crohn’s disease and Ulcerative colitis. Preclinical modelling of intestinal inflammation identified combinatorial TNF and IFN-γ-driven activation of EGC, associated with elevated necroptosis, and negatively impacting gut motility. Genetic-reporter-enabled sorting and downstream analyses confirmed TNF and IFN-γ-driven EGC necroptosis, potentiated by Casp8 deficiency. Furthermore, snRNA-Seq from IBD patient samples confirmed elevated cell death signature in activated but not in rare neuroglia progenitor-like cluster. Conclusion Our findings identify IBD type-associated activated EGC markers involved in immune and epithelial homeoastasis. We uncover necroptosis of activated EGCs as a constituent of intestinal inflammation. Advancing our understanding of activated EGC survival is pivotal in elucidating their complex roles in maintaining gut immune-epithelial homeostasis. What is already known on this topic Activated EGC have emerged as important contributors in maintaining epithelial, immune and neuronal homeostasis. Increasing evidence from mouse studies points to the role of activated EGC in epithelial regeneration, tolerogenic T-cell activation, relaying psychological stress to the enteric nervous system, post-injury neurogenesis, and helminth clearance. Nevertheless, no consensus has emerged on what might define activated EGC in the context of IBD and how EGC turnover is affected in gut inflammation, limiting translation of their disease associated roles. What this study adds By combining bulk with single cell and single nucleus transcriptomes from IBD patients we identified new IBD type– and location-associated EGC activation signatures. Some of these are conserved with mouse EGC in gut inflammation models. We identified osteopontin an immunomodulator and Wnt6 an epithelial morphogen elevated in IBD EGC. We also identified IBD-associated EGC cell clusters, which display higher expression of cell death pathway transcripts. To investigate EGC turnover, we utilized preclinical models and found rapid EGC activation upon Th1/Th17 inflammation. This was associated with elevated EGC activation and caspase-independent necroptotic cell death. Ex vivo experiments showed a combinatorial requirement of IFN-γ and TNF in mediating EGC necroptosis. Our findings were replicated on multiple publicly available sc-RNA sequencing datasets from IBD patients. How this study might affect research, practice or policy Expanding on the available repertoire of EGC activation markers in IBD, both shared and unique to sampling procedure, disease type, and location will provide researchers with tools to identify EGC homeostasis during IBD. Moreover, the nature of the identified markers will stimulate research into specific EGC pathways triggered in inflammation. Adding to this, the rapid induction in pathological death of activated but not naive EGC upon IFN-γ and TNF stimulation will shed light on EGC adaptation and turnover. Our identification of markers of activated EGC with immuno-modulatory and epithelial-regenerative properties, including osteopontin and wingless family of morphogenes will stimulate further research in EGC-immune and EGC-epithelial communication in the context of IBD.

Fields of Study & Subjects

Inflammatory Bowel Disease Mycobacterium research and diagnosis Whipple's Disease and Interleukins

Publication details

Journal / source
Cellular and Molecular Gastroenterology and Hepatology
Publisher
Elsevier BV
Volume
20
Issue
10
Pages
101827–101827
Publication date
1 January 2026
Language
EN